Latest News and Events
January 27, 2026
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Read MoreJanuary 8, 2026
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
Read MoreJanuary 7, 2026
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
Read MoreJanuary 6, 2026
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
Read MoreJanuary 6, 2026
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
Read MoreJanuary 5, 2026
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Read MoreDecember 23, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
Read MoreDecember 15, 2025
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreDecember 8, 2025
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Read MoreDecember 2, 2025
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Read MoreDecember 1, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
Read MoreNovember 24, 2025
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
Read MoreNovember 18, 2025
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Read MoreNovember 4, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
Read MoreOctober 28, 2025
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreOctober 21, 2025
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
Read MoreOctober 7, 2025
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Read MoreSeptember 11, 2025
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
Read MoreSeptember 10, 2025
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Read MoreSeptember 2, 2025
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
Read MoreAugust 27, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
Read MoreAugust 13, 2025
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
Read MoreAugust 1, 2025
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
Read MoreJuly 28, 2025
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
Read MoreJuly 24, 2025
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreJuly 23, 2025
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
Read MoreJuly 8, 2025
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Read MoreJune 23, 2025
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
Read MoreJune 2, 2025
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
Read MoreApril 4, 2025
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreMarch 10, 2025
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
Read MoreMarch 6, 2025
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
Read MoreFebruary 28, 2025
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
Read MoreFebruary 25, 2025
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
Read MoreFebruary 10, 2025
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
Read MoreJanuary 17, 2025
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Read MoreDecember 23, 2024
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
Read MoreDecember 19, 2024
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreDecember 11, 2024
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
Read MoreDecember 3, 2024
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
Read MoreDecember 2, 2024
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
Read MoreNovember 26, 2024
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
Read MoreNovember 18, 2024
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Read MoreNovember 18, 2024
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
Read MoreNovember 4, 2024
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
Read MoreNovember 1, 2024
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
Read MoreOctober 14, 2024
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreSeptember 23, 2024
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
Read MoreSeptember 10, 2024
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
Read MoreSeptember 2, 2024
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Read MoreAugust 21, 2024
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Read MoreAugust 14, 2024
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
Read MoreAugust 8, 2024
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
Read MoreJuly 29, 2024
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreJune 25, 2024
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
Read MoreJune 24, 2024
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
Read MoreJune 3, 2024
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
Read MoreMay 29, 2024
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
Read MoreMay 28, 2024
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
Read MoreMay 20, 2024
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
Read MoreApril 24, 2024
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Read MoreApril 7, 2024
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
Read MoreApril 1, 2024
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreMarch 25, 2024
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
Read MoreMarch 8, 2024
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Read MoreJanuary 5, 2024
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
Read MoreJanuary 3, 2024
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
Read MoreDecember 29, 2023
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreDecember 21, 2023
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
Read MoreDecember 20, 2023
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Read MoreNovember 28, 2023
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
Read MoreNovember 21, 2023
Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
Read MoreNovember 13, 2023
Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
Read MoreNovember 6, 2023
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
Read MoreNovember 2, 2023
Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
Read MoreOctober 31, 2023
GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen
Read MoreOctober 3, 2023
Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences
Read MoreSeptember 27, 2023
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreSeptember 1, 2023
Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences
Read MoreJuly 17, 2023
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
Read MoreJuly 6, 2023
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreJune 27, 2023
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
Read MoreJune 24, 2023
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
Read MoreMay 23, 2023
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
Read MoreMay 16, 2023
Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
Read MoreApril 25, 2023
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
Read MoreApril 4, 2023
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
Read MoreMarch 31, 2023
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreMarch 3, 2023
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
Read MoreFebruary 28, 2023
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Read MoreFebruary 15, 2023
Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
Read MoreFebruary 2, 2023
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Read MoreJanuary 9, 2023
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Read MoreDecember 21, 2022
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
Read MoreDecember 21, 2022
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
Read MoreDecember 20, 2022
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
Read MoreDecember 15, 2022
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreDecember 8, 2022
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Read MoreNovember 21, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
Read MoreNovember 9, 2022
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
Read MoreNovember 7, 2022
Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
Read MoreOctober 13, 2022
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreOctober 11, 2022
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
Read MoreSeptember 1, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
Read MoreAugust 17, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
Read MoreJuly 8, 2022
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreJuly 5, 2022
Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE
Read MoreJune 27, 2022
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
Read MoreMay 26, 2022
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
Read MoreMay 9, 2022
Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives
Read MoreApril 26, 2022
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
Read MoreApril 25, 2022
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
Read MoreApril 6, 2022
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreMarch 24, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
Read MoreMarch 15, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Read MoreFebruary 24, 2022
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
Read MoreFebruary 18, 2022
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Read MoreJanuary 24, 2022
Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
Read MoreJanuary 12, 2022
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
Read MoreDecember 20, 2021
Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
Read MoreDecember 17, 2021
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreNovember 30, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
Read MoreNovember 22, 2021
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
Read MoreNovember 15, 2021
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
Read MoreNovember 12, 2021
Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting
Read MoreNovember 12, 2021
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
Read MoreNovember 1, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
Read MoreOctober 25, 2021
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
Read MoreOctober 12, 2021
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
Read MoreSeptember 30, 2021
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
Read MoreSeptember 29, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences
Read MoreSeptember 1, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
Read MoreJuly 29, 2021
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Read MoreJuly 14, 2021
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Read MoreJuly 6, 2021
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Read MoreJune 30, 2021
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
Read MoreJune 26, 2021
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
Read MoreJune 25, 2021
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
Read MoreJune 23, 2021
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Read MoreJune 21, 2021
Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Read MoreJune 21, 2021
Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Read MoreJune 3, 2021
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
Read MoreApril 28, 2021
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
Read MoreApril 15, 2021
Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
Read MoreMarch 1, 2021
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
Read MoreJanuary 25, 2021
Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
Read MoreDecember 7, 2020
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreNovember 13, 2020
Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020
Read MoreNovember 13, 2020
Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
Read MoreNovember 4, 2020
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Read MoreOctober 8, 2020
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Read MoreSeptember 30, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference
Read MoreSeptember 24, 2020
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreSeptember 16, 2020
Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment
Read MoreSeptember 8, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences
Read MoreAugust 31, 2020
Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
Read MoreAugust 28, 2020
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
Read MoreAugust 18, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences
Read MoreAugust 18, 2020
Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Read MoreAugust 11, 2020
Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
Read MoreJuly 29, 2020
Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
Read MoreJuly 28, 2020
Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
Read MoreJuly 24, 2020
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreJuly 9, 2020
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
Read MoreApril 10, 2020
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis
Read MoreMarch 17, 2020
Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread
Read MoreMarch 17, 2020
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreMarch 3, 2020
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH
Read MoreFebruary 5, 2020
Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Read MoreJanuary 6, 2020
Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer
Read MoreDecember 20, 2019
Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreDecember 16, 2019
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreDecember 16, 2019
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease
Read MoreDecember 13, 2019
Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors
Read MoreDecember 11, 2019
Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Read MoreDecember 6, 2019
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million
Read MoreDecember 4, 2019
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
Read MoreDecember 2, 2019
Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
Read MoreNovember 26, 2019
Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences
Read MoreNovember 18, 2019
Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019
Read MoreNovember 8, 2019
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019
Read MoreOctober 31, 2019
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference
Read MoreOctober 18, 2019
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics
Read MoreOctober 2, 2019
Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics
Read MoreSeptember 30, 2019
Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences
Read MoreSeptember 20, 2019
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreSeptember 16, 2019
Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3
Read MoreAugust 30, 2019
Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences
Read MoreAugust 28, 2019
Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection
Read MoreAugust 8, 2019
Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreJune 27, 2019
Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreJune 21, 2019
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreApril 24, 2019
Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen
Read MoreApril 15, 2019
Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreApril 12, 2019
Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™
Read MoreApril 12, 2019
Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™
Read MoreMarch 29, 2019
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreMarch 18, 2019
Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreMarch 11, 2019
Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
Read MoreJanuary 7, 2019
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
Read MoreJanuary 7, 2019
Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases
Read MoreDecember 17, 2018
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreNovember 9, 2018
Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018
Read MoreNovember 9, 2018
Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018
Read MoreNovember 1, 2018
Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences
Read MoreOctober 15, 2018
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
Read MoreOctober 11, 2018
Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018
Read MoreOctober 4, 2018
Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen
Read MoreSeptember 25, 2018
Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences
Read MoreSeptember 24, 2018
Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics
Read MoreSeptember 21, 2018
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreSeptember 6, 2018
Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit
Read MoreAugust 31, 2018
Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreAugust 30, 2018
Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences
Read MoreJune 29, 2018
Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
Read MoreJune 27, 2018
Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
Read MoreJune 18, 2018
Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreJune 8, 2018
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreMay 30, 2018
Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
Read MoreMay 21, 2018
Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis
Read MoreMay 14, 2018
Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
Read MoreMay 11, 2018
Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline
Read MoreMay 1, 2018
Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics
Read MoreApril 11, 2018
Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™
Read MoreMarch 28, 2018
Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™
Read MoreMarch 27, 2018
Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
Read MoreMarch 20, 2018
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreMarch 12, 2018
Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreFebruary 22, 2018
Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreFebruary 15, 2018
Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
Read MoreJanuary 22, 2018
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million
Read MoreJanuary 18, 2018
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
Read MoreJanuary 17, 2018
Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
Read MoreDecember 27, 2017
Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors
Read MoreDecember 22, 2017
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV
Read MoreDecember 20, 2017
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT
Read MoreDecember 18, 2017
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(C)(4)
Read MoreDecember 6, 2017
Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy
Read MoreOctober 23, 2017
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreOctober 23, 2017
Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017
Read MoreOctober 10, 2017
Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®
Read MoreSeptember 27, 2017
Arrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment
Read MoreSeptember 14, 2017
Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug Candidates
Read MoreSeptember 11, 2017
Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
Read MoreJune 9, 2017
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreApril 24, 2017
Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress™
Read MoreApril 20, 2017
Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™
Read MoreApril 5, 2017
Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™
Read MoreNovember 29, 2016
Arrowhead Pharmaceuticals Focuses Resources on Subcutaneous and Extra-Hepatic RNAi Therapeutics
Read MoreNovember 21, 2016
Arrowhead Pharmaceuticals Announces Closing of License and Collaboration Agreement with Amgen
Read MoreNovember 14, 2016
Arrowhead Pharmaceuticals Presents New Data on ARC-F12 and ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle
Read MoreOctober 20, 2016
Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting®
Read MoreOctober 6, 2016
Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B
Read MoreSeptember 29, 2016
Amgen and Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
Read MoreSeptember 7, 2016
Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521
Read MoreJuly 6, 2016
Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
Read MoreJune 9, 2016
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521
Read MoreJune 3, 2016
Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
Read MoreMay 6, 2016
Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration
Read MoreApril 28, 2016
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521
Read MoreApril 18, 2016
Arrowhead Pharmaceuticals Presents Preclinical Data on Renal Cell Carcinoma Program at AACR 2016
Read MoreApril 13, 2016
Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The International Liver Congress™ 2016
Read MoreJanuary 7, 2016
Arrowhead Begins Dosing the Phase 2b MONARCH Combination Study of ARC-520 in Patients with Chronic Hepatitis B Infection
Read MoreDecember 7, 2015
Arrowhead's ARC-520 Leads to Consistent Immune Reactivation in Chimpanzees with Chronic Hepatitis B Infection
Read MoreNovember 16, 2015
Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA
Read MoreNovember 15, 2015
Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B Infected Chimpanzees
Read MoreOctober 20, 2015
Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015
Read MoreOctober 14, 2015
Arrowhead Presents Overview of Its Broad RNAi Delivery Platform and Introduces New Subcutaneously Administered Format
Read MoreSeptember 24, 2015
Arrowhead Reports Peak Reduction in HBsAg of Up to 99% (1.9 log) After a Single Dose with Hepatitis B Candidate ARC-520 in Treatment Naïve Cohort of Phase 2a Study
Read MoreSeptember 11, 2015
Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System
Read MoreSeptember 10, 2015
Arrowhead to Webcast Analyst Day Presentation on Hepatitis B Candidate ARC-520
Read MoreJuly 8, 2015
Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand
Read MoreJuly 2, 2015
Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency
Read MoreJune 17, 2015
Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520
Read MoreMay 6, 2015
Arrowhead Presents Data on Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic and Thromboembolic Diseases
Read MoreMay 5, 2015
Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT
Read MoreFebruary 23, 2015
Arrowhead Begins Phase 1 Trial of ARC-AAT for Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency
Read MoreFebruary 17, 2015
Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference
Read MoreDecember 29, 2014
CORRECTING and REPLACING Arrowhead Appoints Patrick O'Brien as General Counsel
Read MoreDecember 15, 2014
Arrowhead Files IND for RNAi Therapeutic ARC-520 to Begin Phase 2b Multiple-Dose Studies in Chronic Hepatitis B Patients
Read MoreNovember 18, 2014
Arrowhead to Report Fiscal 2014 Fourth Quarter and Year End Financial Results
Read MoreNovember 18, 2014
Arrowhead Files for Regulatory Permission to Begin Phase 1 Trial of RNAi Therapeutic ARC-AAT
Read MoreNovember 10, 2014
Arrowhead Presents Data on ARC-520 and ARC-AAT at AASLD The Liver Meeting® 2014
Read MoreOctober 8, 2014
Arrowhead to Present ARC-520 Phase 2a Data in Late-Breaking Session at AASLD Liver Meeting® 2014
Read MoreOctober 7, 2014
Arrowhead to Present at 10th Annual Meeting of the Oligonucleotide Therapeutics Society
Read MoreSeptember 30, 2014
Arrowhead Expands Management Team with Appointment of Susan Boynton as Vice President Global Regulatory Affairs
Read MoreSeptember 19, 2014
Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Read MoreAugust 12, 2014
Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520
Read MoreJune 19, 2014
Arrowhead Announces New Clinical Candidate ARC-AAT for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Read MoreJune 13, 2014
Arrowhead Issues a Statement on Intellectual Property Protection for ARC-520
Read MoreApril 1, 2014
Arrowhead Completes Enrollment of First Cohort in Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520
Read MoreMarch 24, 2014
Arrowhead Begins Dosing in Phase 2a Trial of RNAi Therapeutic ARC-520 in Chronic Hepatitis B Patients
Read MoreMarch 3, 2014
Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520
Read MoreFebruary 24, 2014
Arrowhead Closes Underwritten Offering with Gross Proceeds of $120 Million
Read MoreFebruary 20, 2014
Arrowhead to Present at RBC Capital Markets' Global Healthcare Conference
Read MoreFebruary 4, 2014
Arrowhead to Participate in Panel Discussions at 16th Annual BIO CEO & Investor Conference
Read MoreDecember 18, 2013
Arrowhead Reports Fiscal 2013 Fourth Quarter and Year-End Financial Results
Read MoreDecember 11, 2013
Arrowhead to Report Fiscal 2013 Fourth Quarter and Year-End Financial Results
Read MoreDecember 6, 2013
Arrowhead Research Corporation Announces Proposed Public Offering of Common Stock and Warrants
Read MoreNovember 25, 2013
Arrowhead Submits Application to Begin Phase 2a Trial of ARC-520 for the Treatment of Chronic Hepatitis B Infection
Read MoreNovember 4, 2013
Arrowhead Presents Data Suggesting ARC-520 Induces Therapeutic Flare in Chronic Hepatitis B
Read MoreOctober 8, 2013
Arrowhead Completes Enrollment in Phase 1 Study of ARC-520 for the Treatment of Chronic Hepatitis B
Read MoreJuly 23, 2013
Arrowhead Begins Phase 1 Trial of RNAi Therapeutic ARC-520 for Treatment of Chronic Hepatitis B Infection
Read MoreMay 28, 2013
Arrowhead Files to Begin Phase 1 Trial of RNAi Therapeutic ARC-520 Against Chronic Hepatitis B Infection
Read MoreMay 7, 2013
Arrowhead Receives Patent Allowance for DPC siRNA Delivery System with Peptide Backbone
Read MoreMarch 25, 2013
Arrowhead Induces 90% Reduction in Hepatitis B Antigens in Chimpanzee with Chronic Infection: Data Follow Previous Report of Reduction in Viral DNA
Read MoreMarch 14, 2013
Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B
Read MoreMarch 7, 2013
Arrowhead to Host Analyst Event in New York to Discuss RNAi-based Hepatitis B Candidate ARC-520
Read MoreMarch 7, 2013
Arrowhead to Host Analyst Event in New York to Discuss RNAi-based Hepatitis B Candidate ARC-520
Read MoreFebruary 28, 2013
Arrowhead Receives Notice of Patent Allowance for New Protease Sensitive Masking Chemistry for DPC siRNA Delivery System
Read MoreFebruary 26, 2013
Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus
Read MoreJanuary 25, 2013
Arrowhead Announces Pricing of a Public Offering of Common Stock and Warrants
Read MoreJanuary 24, 2013
Arrowhead Research Corporation Announces Proposed Public Offering of Common Stock and Warrants
Read MoreDecember 20, 2012
Arrowhead Reports Fiscal 2012 Fourth Quarter and Year-End Financial Results
Read MoreDecember 18, 2012
Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics
Read MoreDecember 14, 2012
Arrowhead to Report Fiscal 2012 Fourth Quarter and Year-End Financial Results
Read MoreDecember 7, 2012
Arrowhead Announces Pricing of a Public Offering of Common Stock and Warrants
Read MoreNovember 27, 2012
Arrowhead Publishes First Ever Cholesterol-siRNA Mediated Gene Knockdown in Primates and Novel DPC Co-Injection Strategy
Read MoreNovember 13, 2012
Arrowhead Creates Hepatitis B Clinical Advisory Board and Names Dr. Robert Gish Chairman
Read MoreOctober 29, 2012
Arrowhead Presents Data Showing 99% Target Knockdown in Monkeys Without Toxicity Using Subcutaneous Formulation of Dynamic Polyconjugate siRNA Delivery System
Read MoreOctober 16, 2012
Arrowhead Research Receives Notice of Patent Allowance for New Formulation of DPC siRNA Delivery System Showing 500-Fold Increase in Potency
Read MoreSeptember 5, 2012
Arrowhead to Present at Rodman and Renshaw Annual Global Investment Conference
Read MoreAugust 30, 2012
Arrowhead Completes Enrollment in Phase 1b Trial of RNAi Drug Candidate CALAA-01
Read MoreAugust 13, 2012
Arrowhead Raises $6.2 Million through Registered Direct Offering of Common Stock and Warrants
Read MoreAugust 9, 2012
Arrowhead Research to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference
Read MoreJuly 11, 2012
Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide® in a Phase 1 Clinical Trial
Read MoreJune 26, 2012
Arrowhead Announces New Study Demonstrating Rapid Improvement in Pro-Diabetic Metabolic Markers with Anti-Obesity Drug Candidate, Adipotide®
Read MoreJune 6, 2012
Arrowhead Research Advances ARC-520 into IND-Enabling Studies for the Treatment of Hepatitis B and Provides Guidance on Development Timeline
Read MoreApril 11, 2012
Arrowhead Research Corporation Acquires Alvos Therapeutics and Proprietary Library of Targeting Peptides
Read MoreMarch 7, 2012
Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment
Read MoreMarch 5, 2012
Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance and Master Services Agreement for RNAi Therapeutics
Read MoreFebruary 29, 2012
Arrowhead Announces Patent Issuance Covering siRNA Inhibitors of HIF-2α (EPAS1)
Read MoreJanuary 4, 2012
Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial
Read MoreDecember 20, 2011
Arrowhead Reports Fiscal 2011 Fourth Quarter and Year-End Financial Results
Read MoreDecember 15, 2011
Arrowhead to Report Fiscal 2011 Fourth Quarter and Year-End Financial Results
Read MoreNovember 27, 2011
Arrowhead Research Publishes White Paper on RNAi Delivery Technology Acquired from Roche
Read MoreNovember 23, 2011
Arrowhead Research Appoints Drs. David Lewis and David Rozema to Lead Operations at Madison, WI Facility
Read MoreNovember 14, 2011
Leonardo Biosystems Receives Second $1.25 Million Investment from the Texas Emerging Technology Fund
Read MoreNovember 10, 2011
Arrowhead Research Subsidiary Ablaris Therapeutics Data Published in Science Translational Medicine Demonstrates Weight Loss in Obese Monkeys
Read MoreNovember 3, 2011
Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer
Read MoreNovember 2, 2011
Vascular Research Further Validates the Drug Development Programs of Arrowhead Research Subsidiary Ablaris Therapeutics and Alvos Therapeutics
Read MoreAugust 1, 2011
Arrowhead Research to Report Fiscal 2011 Third Quarter Financial Results and Host Conference Call on Monday, August 8, 2011
Read MoreJuly 26, 2011
Arrowhead Research Announces Oncology Expert Timothy J. Triche to Join Calando Scientific Advisory Board
Read MoreJune 16, 2011
Arrowhead Research President & CEO Christopher Anzalone Featured in The Wall Street Transcript Interview
Read MoreJune 9, 2011
Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement
Read MoreMay 4, 2011
Arrowhead Research to Report Fiscal 2011 Second Quarter Financial Results and Host Conference Call on Thursday, May 12, 2011
Read MoreMay 3, 2011
Arrowhead Research to Present at the 2011 MDB Capital Group Bright Lights Conference on May 10
Read MoreApril 27, 2011
ARROWHEAD RESEARCH ANNOUNCES RNAI LEADER JOHN J. ROSSI, PH.D. TO JOIN CALANDO SCIENTIFIC ADVISORY BOARD
Read MoreMarch 8, 2011
Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16
Read MoreFebruary 9, 2011
Arrowhead Research to Present at the 13th Annual BIO CEO & Investor Conference
Read MoreFebruary 6, 2011